Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: Comparison with commercial preparations

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 68, Issue 2, 2008, Pages 283-288

  Vogt, Markus ^a,b   Kunath, Klaus ^b   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MERCK KGAA   (Germany)

Author keywords

Biorelevant media; Cogrinding; Dissolution rate enhancement; Fenofibrate; Jet milling; Micronization; Particle size reduction; Spray drying

Indexed keywords

DODECYL SULFATE SODIUM; FENOFIBRATE; LACTOSE; NANOPARTICLE; POVIDONE;

ARTICLE; CHEMICAL PROCEDURES; CRYSTAL; DIFFERENTIAL SCANNING CALORIMETRY; DRUG MARKETING; DRUG SOLUBILITY; GRINDING; INTERMETHOD COMPARISON; MICRONIZATION; PARTICLE SIZE; SOLID STATE; SPRAY DRYING; X RAY DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; PROCETOFEN; SOLUBILITY; X-RAY DIFFRACTION;

EID: 37849030370     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2007.05.010     Document Type: Article

References (28)

1. Hancock B.C., and Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86 (1997) 1-12
2. Grau M.J., Kayser O., and Müller R.H. Nanosuspensions of poorly soluble drugs - reproducibility of small scale production. Int. J. Pharm. 196 (2000) 155-157
3. Liversidge G.G., and Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125 (1995) 91-97
4. Hargrove J.T., Maxson W.S., and Wentz A.C. Absorption of oral progesterone is influenced by vehicle and particle size. Am. J. Obstet. Gynecol. 161 (1989) 948-951
5. Jounela A., Pentikainen P., and Sothmann A. Effect of particle size on the bioavailability of digoxin. Eur. J. Clin. Pharmacol. 8 (1975) 365-370
6. Shakhtshneider T.P., Vasiltchenko M.A., Politov A.A., and Boldyrev V.V. The mechanochemical preparation of solid disperse systems of ibuprofen-polyethylene glycol. Int. J. Pharm. 130 (1996) 25-32
7. Sugimoto M., Okagaki T., Narisawa S., Koida Y., and Nakajima K. Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using water soluble-polymer. Int. J. Pharm. 160 (1998) 11-19
8. G.G. Liversidge, K.C. Cundy, J.F. Bishop, D.A. Czekai, Nano Systems LLC, Surface modified drug nanoparticles, US Patent 5,145,684, 1992.
9. J.A. Bruno, B.D. Doty, E. Gustow, K.J. Illig, N. Rajagopalan, P. Sarpotdar, Method of grinding pharmaceutical substances, US Patent 5,518,187, 1996.
10. Bodmeier R., and Chen H. Indomethacin polymeric nanosuspensions prepared by microfluidization. J. Contr. Rel. 12 (1990) 223-233
11. Sebhatu T., Angberg M., and Ahlneck C. Assessment of the degree of disorder in crystalline solids. Int. J. Pharm. 101 (1994) 237-247
12. Munoz A., Guichard J.P., and Reginault P. Micronised fenofibrate. Atherosclerosis 110 Suppl. (1994) S45-S48
13. Adkins J.C., and Faulds D. Micronised fenofibrate: a review of its pharmacodynamicproperties and clinical efficacy in the management of dyslipidemia. Drugs 54 (1997) 615-633
14. Guichard J.P., Blouquin P., and Qing Y. A new formulation of fenofibrate: suprabioavailable tablets. Curr. Med. Res. Opin. 16 (2000) 134-138
15. Sheu M.T., Yeh C.M., and Sokoloski T.D. Characterization and dissolution of fenofibrate solid dispersion systems. Int. J. Pharm. 103 (1994) 137-146
16. Palmeiri G.F., Antonini I., and Martelli S. Characterization and dissolution studies of PEG4000/fenofibrate solid dispersions. STP Pharm. Sci. 6 (1996) 188-194
17. Dressman J.B., and Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 11 (2000) S73-S80
18. Barth H.G. Modern Methods of Particle Size Analysis (1984), John Wiley & Sons, New York
19. Mithani S.D., Bakatselou V., TenHoor C.N., and Dressman J.B. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm. Res. 13 (1996) 163-167
20. Glomme A., März J., and Dressman J.B. Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities. In: Testa B., Krämer S., Wunderli-Allensprach H., and Folkers G. (Eds). Pharmacokinetic Profiling in Drug Research (2005), Wiley-VCH, Zurich, Switzerland 259-280
21. Taylor L.S., and Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersion. Pharm. Res. 14 (1997) 1691-1698
22. Doherty C., and York P. Accelerated stability of an X-ray amorphous furosemide-poly(vinylpyrrolidone) solid dispersion. Drug Dev. Ind. Pharm. 15 (1989) 1969-1987
23. Sekikawa H., Nakano M., and Arita T. Inhibitory effect of polyvinylpyrrolidone on the crystallization of drugs. Chem. Pharm. Bull. 26 (1978) 118-126
24. Simonelli A.P., Mehta S.C., and Higuchi W.I. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. J. Pharm. Sci. 59 (1970) 633-638
25. Ziller K.H., and Rupprecht H. Control of crystal growth in drug suspensions. Drug Dev. Ind. Pharm. 14 (1988) 2341-2370
26. Otsuka M., Ofusa T., and Matsuda Y. Dissolution improvement of water-insoluble glybuzole by co-grinding and co-melting with surfactants and their physicochemical properties. Colloids Surf. B: Biointerfaces 10 (1998) 217-226
27. Ibrahim H.G., Pisano E., and Bruno A. Polymorphism of phenylbutazone: properties and compressional behavior of crystals. J. Pharm. Sci. 66 (1977) 669-673
28. Elamin A.A., Ahlneck C., Alderborn G., and Nyström C. Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure. Int. J. Pharm. 111 (1994) 159-170